Second primary malignancies in multiple myeloma: A review.

Area of Science:

• Oncology
• Hematology
• Cancer Survivorship

Background:

• Improving survival in multiple myeloma (MM) has increased focus on long-term risks like second primary malignancies (SPMs).
• Historical data show a higher incidence of hematologic SPMs, particularly acute leukemia, in MM survivors.
• Treatment modalities like alkylating agents and autologous stem cell transplantation have been linked to increased SPM risk.

Purpose of the Study:

• To review the current understanding of SPMs in MM survivors.
• To explore the influence of host, disease, and treatment factors on SPM incidence.
• To highlight emerging screening guidelines and prognosis for SPMs in this population.

Main Methods:

• Literature review of population studies and clinical data concerning MM survivors and SPM incidence.
• Analysis of treatment-related factors, including alkylators, immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies.
• Synthesis of information on host and disease factors contributing to SPM risk.

Main Results:

• Alkylating agents (e.g., melphalan) and autologous stem cell transplantation are associated with increased SPM risk.
• Immunomodulatory drugs like lenalidomide show an increased SPM incidence, though benefits often outweigh risks.
• Newer therapies (proteasome inhibitors, monoclonal antibodies) appear not to increase SPM risk, but long-term data are limited.

Conclusions:

• SPMs are a significant long-term consideration for MM survivors.
• Treatment selection and patient factors influence SPM risk.
• Ongoing research and updated screening protocols are crucial for managing SPM risk in MM survivors.